Figure 1.

Solute carrier (SLC) uptake transporters as chemotherapeutic drug targets to increase efficacy or reduce toxicity: (A) Transporter-mediated accumulation of a chemotherapeutic agent conjugated to an endogenous substrate of an SLC transporter, which may be cleaved [125] or act as a conjugate [126]. (B) SLC transporter inhibition stops the accumulation of growth promoting factors [127]. (C) Coadministration of a chemotherapeutic drug and an inhibitor of efflux transporter [128]. (D) Ct-OATP1B3-specific chemotherapeutic substrates to enhance tumor cell accumulation sparing healthy tissue expressing lt-OATP1B3 [129]. (E) Identification of genetic variants exhibiting superior transport capacity as compared to the wildtype that could allow personalized medication and dose finding [41]. (F) Inhibition of an SLC transporter in healthy tissue such as the kidney in order to reduce toxic side effects [130].